CORE--CYTOGENETICS AND FISH

这个核心的功能与原来的授权没有变化。 基本上，这个核心的设计是为了执行必要的实验室测试 慢性粒细胞白血病患者造血细胞的常规表型分析 进入治疗阶段的慢性期和急变期 图1-2和表一中所列的方案和实验室分析。 包括BCR的光形态、超微结构、Southern杂交 重排，免疫表型和细胞遗传学，以建立 慢性粒细胞白血病的诊断。仅对细胞遗传学分析请求支持 评估费城染色体百分比所需的 骨髓、外周血中的阳性(Ph+)细胞 治疗后患者CD34+选择的细胞(方案1A-D)。这个 使用的细胞遗传学分析将不仅包括经典的G显带 方法还包括最新发展的荧光原位杂交 (FISH)检测9；22染色体易位的方法 染色体特异的DNA探针。我们的初步研究表明 FISH方法可以有效地用于检测9；22易位 在分布较差的中期和间期核中 用常规的细胞遗传学方法无法分析。因此，纳入 在核心使用鱼应该会显著提高我们的能力 评价治疗效果及收集策略 自体移植的正常二倍体祖细胞。这个核心也应该 允许我们将鱼类与细胞遗传学进行比较，以确定前者是否 在检测慢性粒细胞白血病微小残留病方面优于后者 因为他预测复发。细胞遗传学和FISH分析的结果将 还应与项目II-VI中其他化验的结果相关联。

The function of this core is not changed from the original grant. Basically, this core is designed to perform necessary laboratory tests for the routine phenotyping of the hematopoietic cells from CML patients in chronic phase and blast crisis who are entered on the therapeutic protocols and laboratory analysis listed in Figures 1-2 and Table I. These include light morphology, ultrastructure, Southern blots for bcr rearrangement, immunophenotype, and cytogenetics to establish the diagnosis of CML. Support is requested only for cytogenetic analyses required for the evaluation of the percentage of Philadelphia-chromosome positive (Ph+) cells in the bone marrow, pheresed peripheral blood, or CD34+ selected cells of patients following therapy (Project 1A-D). The cytogenetic assays used will include not only the classical G-banding method but also the newly-developed fluorescent in situ hybridization (FISH) method that detects the 9;22 chromosomal translocation by using chromosome-specific DNA probes. Our preliminary studies demonstrated that the FISH method could be effectively used to detect the 9;22 translocation in poorly-spread metaphases and in interphase nuclei that were otherwise unanalyzable by the routine cytogenetic methods. Therefore, the inclusion of the use of FISH in the Core should significantly improve our ability to evaluate the effectiveness of therapy and the strategies for collecting normal diploid progenitor cells for autografts. This Core should also allow us to compare FISH with cytogenetics to determine if the former is better than the latter for detecting minimal residual disease in CML and for predicting relapse. The Results of cytogenetic and FISH analyses will also be correlated with results from other assays in Projects II-VI.